본문 바로가기
KERD
논문KCI 등재

Clinical severity according to the primary infection variant in patients with suspected SARS-CoV-2 reinfection in Korea

황인섭|김종헌|Park Hanul|Hwang Myung-Jae|Park Chungmin|Son Taejong
한국역학회 (Korean Society of Epidemiology)|2023.01|Epidemiology and Health|제45권 |pp. 1-5|DOI 10.4178/epih.e2023007

4

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19VaccinationDisease severityOmicronReinfection

초록

OBJECTIVES: We aimed to evaluate the severity of suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection according to variants of concern in Gyeongsangbuk-do and Daegu, Korea. METHODS: The database of coronavirus disease 2019 (COVID-19) cases reported from epidemiological investigations through the integrated system operated by the Korea Disease Control and Prevention Agency, from January 20, 2020 to May 7, 2022 was combined with data from the Health Insurance Review and Assessment Service system. The severity odds ratio (SOR) in secondary infection episodes compared with primary infection was estimated using a generalized linear model with a binomial distribution. RESULTS: In all patients, the SOR of SARS-CoV-2 reinfection was 0.89 (95% confidence interval [CI], 0.82 to 0.95), and the severity was lower than in the first infection. Patients who had been vaccinated within 91 days showed a more attenuated SOR (0.85; 95% CI, 0.74 to 0.98). However, despite vaccination, in patients with both primary and secondary infections caused by the Omicron variant, the severity was reduced to a lesser extent than in patients primarily infected with other variants. CONCLUSIONS: We could make efforts to relieve the severity of COVID-19 in vulnerable populations, in which death is more likely, by recommending booster vaccinations in case of a resurgence.

Abstract

OBJECTIVES: We aimed to evaluate the severity of suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection according to variants of concern in Gyeongsangbuk-do and Daegu, Korea. METHODS: The database of coronavirus disease 2019 (COVID-19) cases reported from epidemiological investigations through the integrated system operated by the Korea Disease Control and Prevention Agency, from January 20, 2020 to May 7, 2022 was combined with data from the Health Insurance Review and Assessment Service system. The severity odds ratio (SOR) in secondary infection episodes compared with primary infection was estimated using a generalized linear model with a binomial distribution. RESULTS: In all patients, the SOR of SARS-CoV-2 reinfection was 0.89 (95% confidence interval [CI], 0.82 to 0.95), and the severity was lower than in the first infection. Patients who had been vaccinated within 91 days showed a more attenuated SOR (0.85; 95% CI, 0.74 to 0.98). However, despite vaccination, in patients with both primary and secondary infections caused by the Omicron variant, the severity was reduced to a lesser extent than in patients primarily infected with other variants. CONCLUSIONS: We could make efforts to relieve the severity of COVID-19 in vulnerable populations, in which death is more likely, by recommending booster vaccinations in case of a resurgence.

참고문헌 (16)

  1. Hu T, "A comparison of COVID-19, SARS and MERS", PeerJ, pp.e9725~ (2020)
  2. Gaudreault NN, "Experimental re-infected cats do not transmit SARS-CoV-2", Emerg Microbes Infect, 10, pp.638~650 (2021)
  3. Brustolin M, "Protection against reinfection with D614-or G614-SARS-CoV-2 isolates in golden Syrian hamster", Emerg Microbes Infect, 10, pp.797~809 (2021)
  4. Deng W, "Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques", Science, 369, pp.818~823 (2020)
  5. "Tracking SARS-CoV-2 variants"[URL]
  6. Davies NG, "Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England", Science, 372, pp.eabg3055~ (2021)
  7. Graham MS, "Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1. 1. 7 : an ecological study", Lancet Public Health, 6, pp.e335~e345 (2021)
  8. Ren X, "Reinfection in patients with COVID-19 : a systematic review", Glob Health Res Policy, 7, pp.12~ (2022)
  9. Pulliam JR, "Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa", Science, 376, pp.eabg3055~ (2022)
  10. Park AK, "Reinfection of COVID-19 in the Republic of Korea", Public Health Wkly Rep, 14, pp.2000~2004 (2021)
  11. "COVID-19 treatment guidelines: clinical spectrum of SARS-CoV-2 infection"[URL]
  12. Mensah AA, "Disease severity during SARS-COV-2 reinfection : a nationwide study", J Infect, 84, pp.542~550 (2022)
  13. Sigal A, "Estimating disease severity of Omicron and Delta SARS-CoV-2 infections", Nat Rev Immunol, 22, pp.267~269 (2022)
  14. Nyberg T, "Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron(B. 1. 1. 529)and delta(B. 1. 617. 2)variants in England : a cohort study", Lancet, 399, pp.1303~1312 (2022)
  15. Israel A, "Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection : test negative design study", BMJ, 375, pp.e067873~ (2021)
  16. Goldberg Y, "Protection and waning of natural and hybrid immunity to SARS-CoV-2", N Engl J Med, 386, pp.2201~2212 (2022)

관련 논문AI추천

Clinical Characteristics of Patients Who Contracted the SARS-CoV-2 Omicron Variant from an Outbreak in a Single Hospital김영근, 김예진, 김은미, 손유진, 오원섭, Pyo Jin Shin연세대학교의과대학 · Yonsei Medical Journal2022 · 제63권 제8호Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak박상원, 이은영, Lee Chan Mi대한감염학회 · Infection and Chemotherapy2022 · 제54권 제2호Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance강지은, 강형구, 곽이경, 구현경, 이명진, Choi Sang Bong, Kang Jiyeon, Kim Baek-Nam, Lee Hyuk Pyo, Park Hye Kyeong, Song Je Eun대한감염학회 · Infection and Chemotherapy2022 · 제54권 제4호Correlation between Clinical Severity and Cycle Threshold Values of Real-time RT-PCR at the Time of Admission in COVID-19 Patients김상경, 유은형, 이아진, 전창호대한진단검사의학회 · Laboratory Medicine Online2023 · 제13권 제4호Viral shedding patterns of symptomatic SARS-CoV-2 infections by periods of variant predominance and vaccination status in Gyeonggi Province, Korea김종헌, 이순영, Choi Gawon, Choi Sojin, Lim Ah-Young, Park Kunhee한국역학회 · Epidemiology and Health2023 · 제45권 Clinical Characteristics and Risk Factors for Severe Disease of Coronavirus Disease 2019 in a Low Case Fatality Rate Region in Korea김미선, 오현주, 유정래, 이향란, 허상택대한감염학회 · Infection and Chemotherapy2021 · 제53권 제4호

이 간행물의 다른 논문 (102건)

Changes in health behaviors and obesity of Korean adolescents before and during the COVID-19 pandemic: a special report using the Korea Youth Risk Behavior SurveyChoi Sunhye, Oh Kyungwon, 오창모, Kim Yangha, Yang Ji Eunpp. 1-8Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample황태윤, 오경재, 홍영습, Kim Su Young, 이계오, 윤규현, 김정애, 이혁민, 신민호, 이순영, 이원영, 김동현, 박재현, 이훈재, 조성일, 남해성, 이무식, Lee June-Woo, Kim Sung Soon, 설로마, Kim Byoungguk, 이중정, 오창모, Jung Sun Jae, 오성수, Yim Hyeon Woo, 한미아, 김유미, 조희숙, Lee Ju-Hyung, Jung Jaehun, Kim Ah-Ra, Han Jina, Baek Hye Jin, Noh Eunbi, Ryu Sukhyun, 박노례, Jung Eunok, Kim Sang Il, Hwang Yoo-Sung, Oh Sangcheol, Kim Migyeong, Yu Byengchul, Kim Keonyeop, Hwangbo Young, Lee Joongyub, Kim Hyeongsu, Kang Gilwon, Ryu So Yeon, Park Soon-Woo, Kim Sang Kyu, Park Ki Soo, Kwon Jun-wook, Jang Eun Young, Nam Jeonghyunpp. 1-13Genetically determined alcohol consumption and cancer risk in Korea지선하, 정금지, 백지우, Shin Sang Yoppp. 1-7Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea고미정, 김형준, 황인섭, Kwon Yunhyung, Kim Seontae, Seo Soon-Young, Cho Enhi, Yeon-Kyeng Leepp. 1-7Detecting mpox infection in the early epidemic: an epidemiologic investigation of the third and fourth cases in KoreaChoi Jihyun, Choi Yunsang, Kim Jong Mu, 박숙경, Kim Taeyoung, Park Eonjoo, Eun Juk Suk, Lee Eun-young, Mun Ji Won, Lee Sinyoung, Yeom Hansol, Kim Eun Kyoung, Ha Jinhopp. 1-7
원문 보기